4//SEC Filing
Pacira Pharmaceuticals, Inc. 4
Accession 0001181431-13-057966
$PCRXCIK 0001396814operating
Filed
Nov 7, 7:00 PM ET
Accepted
Nov 8, 7:17 PM ET
Size
15.0 KB
Accession
0001181431-13-057966
Insider Transaction Report
Form 4
Markvicka Taunia
Vice President, Commercial
Transactions
- Sale
Common Stock
2013-11-06$50.60/sh−28,394$1,436,850→ 21,606 total - Sale
Common Stock
2013-11-06$52.49/sh−5,681$298,218→ 1,802 total - Sale
Common Stock
2013-11-06$51.36/sh−14,123$725,301→ 7,483 total - Exercise/Conversion
Common Stock
2013-11-06$10.81/sh+50,000$540,500→ 50,000 total - Sale
Common Stock
2013-11-06$53.61/sh−1,802$96,611→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2013-11-06−50,000→ 100,000 totalExercise: $10.81Exp: 2022-06-04→ Common Stock (50,000 underlying)
Footnotes (6)
- [F1]The exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.00, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.01 to $51.85, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.21 to $53.14, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.40 to $53.78, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) of this Form 4.
- [F6]The stock option vests as follows: 25% of the options vested on June 5, 2013; the remaining options vest in successive equal monthly installments over the subsequent 36 months.
Documents
Issuer
Pacira Pharmaceuticals, Inc.
CIK 0001396814
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001396814
Filing Metadata
- Form type
- 4
- Filed
- Nov 7, 7:00 PM ET
- Accepted
- Nov 8, 7:17 PM ET
- Size
- 15.0 KB